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Abstract
Background: Estrogen suppresses microglial activation and extravasation of circulating
monocytes in young animals, supporting an anti-inflammatory role for this hormone. However, the
mechanisms underlying estrogen's anti-inflammatory effects, especially in vivo, are not well
understood. The present study tests the hypothesis that anti-inflammatory effects of estrogen are
mediated by the pan-neurotrophin receptor p75NTR. Previously, we reported that estrogen
attenuated local increases of interleukin(IL)-1β in the NMDA-lesioned olfactory bulb, while further
increasing NGF expression.
Results: The present studies show that this lesion enhances expression of the neurotrophin
receptor p75NTR at the lesion site, and p75NTR expression is further enhanced by estrogen
treatment to lesioned animals. Specifically, estrogen stimulates p75NTR expression in cells of
microvessels adjacent to the lesion site. To determine the role of this receptor in mediating
estrogen's anti-inflammatory effects, a p75NTR neutralizing antibody was administered at the same
time the lesion was created (by stereotaxic injections of NMDA) and specific markers of the
inflammatory cascade were measured. Olfactory bulb injections of NMDA+vehicle (preimmune
serum) increased IL-1β and activated the signaling molecule c-jun terminal kinase (JNK)-2 at 6 h.
At 24 h, the lesion significantly increased matrix metalloproteinase (MMP)-9 and prostaglandin
(PG)E2, a COX-2 mediated metabolite of arachadonic acid. All of these markers were significantly
attenuated by estrogen in a time-dependent manner. However, estrogen's effects on all these
markers were abolished in animals that received anti-p75NTR.
Conclusion: These data support the hypothesis that estrogen's anti-inflammatory effects may be,
in part, mediated by this neurotrophin receptor. In view of the novel estrogen-dependent
expression of p75NTR in cells associated with microvessels, these data also suggest that the blood
brain barrier is a critical locus of estrogen's neuro-immune effects.
Published: 12 September 2005
BMC Neuroscience 2005, 6:58 doi:10.1186/1471-2202-6-58
Received: 29 March 2005
Accepted: 12 September 2005
This article is available from: http://www.biomedcentral.com/1471-2202/6/58
© 2005 Nordell et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 18
(page number not for citation purposes)
BMC Neuroscience 2005, 6:58 http://www.biomedcentral.com/1471-2202/6/58Background
Estrogen replacement in adult female rats is neuroprotec-
tive for a variety of experimentally induced neural injury
models, such as ischemia [1-3], toxins [4-6], and forebrain
transections [7]. Estrogen is an important modulator of
the neural inflammatory response, principally via its
actions on microglia, the brain-resident immune cell. In
primary cultures of microglia or in glial cell lines, estrogen
pretreatment attenuates lipopolysaccharide (LPS)-
induced superoxide release, phagocytic activity [8] and
inducible nitric oxide synthase (iNOS) [8-11]. In vivo,
estrogen treatment prevents the activation of microglia
and recruitment of monocytes following injections of LPS
[6], and attenuates expression of the inflammatory
cytokine interleukin (IL)-1β following excitotoxic lesions
[5].
The mechanisms by which estrogen exerts an anti-inflam-
matory effect, especially in vivo, remain poorly under-
stood. In this report, we test the hypothesis that estrogen's
anti-inflammatory effects are mediated via the neuro-
trophin family of growth factors and receptors. Members
of this family include nerve growth factor (NGF), brain-
derived neurotrophic factor (BDNF) and neurotrophins
(NT)-3 and 4/5. Although first identified by their potent
effects on neuronal survival and differentiation, NGF and
BDNF are widely distributed and have a broad range of
effects. BDNF, for example, is widely synthesized in the
vascular system [12-15] and NGF is synthesized in
immune cells (for review see [16]). Local NGF expression
increases dramatically following a variety of injurious
stimuli [17-19] and may prevent toxic effects of other
inflammatory cytokines [20].
P75NTR, the pan neurotrophin receptor which binds NGF
and all the known neurotrophins, also increases following
neuronal injury [21,22]. This increase may be associated
with glia [23] and endothelial cells [24]. Several studies
have shown that NGF, when bound to p75NTR, initiates
apoptosis in several cell types (reviewed in [25]) and
recent evidence suggests that pro-NGF may preferentially
bind p75NTR and initiate apoptosis [26,27]. P75NTR-
NGF interactions have also been implicated in suppress-
ing the immune response by inhibiting the induction of
major histocompatibility complex (MHC) class II pro-
teins [28] and by suppressing the transmigration of circu-
lating immune cells to the brain [24,29].
Although classified as a neurotrophin receptor, p75NTR
may also be considered a member of the tumor necrosis
factor receptor (TNFR) family, due to the presence of spe-
cific domains called TRAF-interacting motifs or TIMs [30].
TRAF's are TNFR-associated factors, and recruitment of
these factors by TIM-containing members of the TNFR
family results in the activation of multiple signaling path-
ways such as NFkB, JNK, ERK and PI-3K, which lead to
immune and inflammatory responses as well as cell sur-
vival and differentiation (for review see [31]). P75NTR
has been shown to bind recruitment molecules such as
the interleukin-receptor associated kinase (IRAK) [32],
which are typically recruited by IL ligand-receptor com-
plexes to activate NFkB and to initiate a pro-inflammatory
cascade. Although the downstream consequences of
p75NTR-IRAK interactions are not well known, one possi-
bility is that p75NTR competes with IL-1β for this mole-
cule, and may thus attenuate the inflammatory cascade
initiated by the interleukins.
The present study was designed to determine the mecha-
nism of estrogen's anti-inflammatory effect in lesioned
forebrain of young adult females. Specifically, we exam-
ined whether estrogen interacted with the pan-neuro-
trophin receptor p75NTR to suppress the inflammatory
cascade. Following brain injury, there is a rapid synthesis
and release of inflammatory cytokines such as IL-1β.
These cytokines activate signaling intermediaries such as
NFkB and JNK to initiate the transcription of downstream
inflammatory genes. We tested the effects of bulb lesions
on key portions of this cascade (IL-1β expression, JNK
activation, PGE2 and MMP-9 expression) in animals that
were given either estrogen or control pellets. The role of
p75NTR was evaluated by using a neutralizing antibody
to this receptor, injected into the lesion site. In the present
study, we used NMDA-induced olfactory bulb lesions,
which we have previously shown results in an inflamma-
tory response as indicated by microglial activation and
increases in IL-1β [5]. Here we report that olfactory bulb
lesions to ovariectomized females increase p75NTR
expression, and receptor expression is further enhanced in
females that received estrogen treatment. Specifically,
estrogen treatment stimulates p75NTR expression in cells
associated with microvessels. Antibody experiments
reveal that while estrogen treatment suppresses the
inflammatory cascade resulting from bulb lesions, block-
ing the p75NTR receptor completely abolishes estrogen's
effects on the early and late markers of the inflammatory
cascade, but has no effect on these markers in controls
(non-estrogen treated animals). These data support the
hypothesis that estrogen's anti-inflammatory effects are
mediated through p75NTR. In view of our recent studies
that estrogen reduces extravasation of dye from circula-
tion to brain tissue [33] and the current evidence that
estrogen stimulates p75NTR expression in the wall of
microvessels, we propose that early in the course of brain
injury, estrogen pretreatment suppresses the inflamma-
tory cascade by affecting the blood brain barrier.Page 2 of 18
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Confirmation of estrogen treatment
Plasma estradiol levels were measured from trunk blood
collected at termination (approximately three weeks after
pellet implantation). Ovariectomized animals replaced
with an estrogen-containing pellet (E2) had average
plasma estradiol levels of 51.66 ± 4.19 pg/ml, typical of
levels seen at proestrus in this animal. The average weight
gain as a result of estrogen treatment was -6.24 ± 2.1 g. In
contrast, ovariectomized, control pellet-replaced animals
(OVX) had low estradiol levels (9.1 ± 0.49 pg/ml) with a
corresponding weight gain of 57.5 ± 2.76 g.
Confirmation of anti-p75NTR antibody treatment
In the present studies, the effectiveness of anti-p75NTR
antibodies was tested in vivo by measuring caspase-3 activ-
ity. Caspase-3, an effector caspase that is proximal to the
apoptotic cell death cascade [34], was used as a marker
since p75NTR has been implicated in apoptotic cell death.
Caspase-3 activity was significantly reduced (by 40%, p <
0.05) in animals that received NMDA+anti-p75NTR anti-
body (0.73 ± 0.06 pmol AMC liberated/min at 37°C/mg
protein) as compared to animals that received
NMDA+preimmune serum (1.23 ± 0.04 pmol AMC liber-
ated/min at 37°C/mg protein).
Specificity of the actions of the p75NTR antibody was not
tested directly, by the use of non-specific antibody or anti-
body to an unrelated protein. However, as described
below, the actions of the antibody were seen only in estro-
gen-treated animals and not in control-treated animals.
Furthermore, the actions of the antibody reversed estro-
gen's actions on inflammatory markers (see Figures 3, 5, 6
and 7), but did not reverse estrogen's effects on the neuro-
trophin NGF (see Figure 8).
P75NTR regulation following olfactory bulb lesions
P75NTR expression in olfactory bulb lysates was deter-
mined by Western blot assay (Figure 1A), and the quanti-
tated signal, normalized to JNK, is shown in a histogram
in Figure 1B. P75NTR expression increased 3-4 fold in
lesioned animals as compared to sham-injected animals
(F1,20: 12.2; p < 0.05). Estrogen treatment further
enhanced the level of lesion-induced p75NTR (F1,20: 4.99,
p < 0.05). As reported before, this is the group where
expression of the inflammatory cytokine IL-1β is attenu-
ated by estrogen [5]. The p75NTR antibody used in West-
ern blot assays recognized a size-appropriate band in
olfactory bulb tissue and PC12 cells, a prototypic p75NTR
positive cell line.
P75NTR immunohistochemistry
P75NTR expression in the olfactory bulb of sham and
lesioned animals was determined by immunofluores-
cence (Figure 2), using the same antibody that was used
for Western blot analysis. A few sections were also probed
with the neutralizing p75NTR antibody. Figure 2a shows
the cellular architecture of the olfactory bulb in a section
stained with a nuclear dye (DAPI). With either p75NTR
antibody, prominent staining was noted in the fibers of
the glomerular layer of lesion and sham-injected animals
(Figure 2b; taken from region indicated by solid-line box
in 2a), similar to that reported by others [35]. While the
central portion of the bulb was poorly immunoreactive
for p75NTR in the sham-lesion animals (Figure 2c),
NMDA injections resulted in bright staining in fibers and
cells surrounding the lesion site (Figure 2d). Although the
type of cell and fibers is not known currently, the pattern
of staining did not appear to be any different in the estro-
gen-replaced and estrogen-deprived animals. This diffuse
staining pattern likely accounts for the bulk of p75 expres-
sion observed following lesions in the Western blot anal-
ysis. The only location where p75NTR expression differed
in estrogen- and control-treated lesioned animals was
associated with blood vessels. P75NTR-positive staining
was visible in cells lining microvessels near the lesion site
in estrogen-treated animals (Figure 2e and 2g). Typically,
these vessels contained one or two curved nuclei, charac-
teristic of endothelial cells (visualized by DAPI, Figure 2f
and 2h), indicating that these vessels were either capillar-
ies or postcapillary venules. A high magnification image
from a section of an estrogen-treated animal photo-
graphed under both UV and fluorescein illumination,
shown in Figure 2i, depicts p75NTR (in green) localized
to a cell lining the vessel wall, identified by its curved
nucleus (in blue). While microvessel staining was easily
seen in the estrogen-treated animals, there was virtually
no p75NTR staining seen in microvessels in the control
pellet replaced animals (Figure 2j; nuclear stain in 2k) and
in control sections from lesioned, estrogen-replaced ani-
mals where the primary antibody was not applied (Figure
2l; nuclear stain in 2m). Photomicrographs (e) through
(m) were obtained from the region indicated by the
hatched box shown in 2a.
Markers of inflammation
To test if p75NTR mediates the anti-inflammatory effects
of estrogen, control and estrogen-pellet replaced animals
were injected with NMDA+anti-p75NTR, and compared
to sham lesioned controls and controls that received
NMDA+preimmune serum. Animals were either termi-
nated 6 or 24 h after the lesion, and olfactory bulb protein
lysates were used to measure several proteins associated
with the inflammatory cascade.
IL-1β expression
Local levels of IL-1β, measured by ELISA assay, increased
dramatically at 6 h (F2,30: 51.61, p < 0.05) and 24 h (F2,30:
39.31, p < 0.05) after NMDA injections (Figure 3). At 6 h
after lesion, estrogen treated groups had slightly lowerPage 3 of 18
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p < 0.05). At 24 hours after lesion, estrogen replacement
(OVX+E) clearly blunted the injury-related increase in IL-
1β (F2,30: 4.99, p < 0.05). However, neutralizing p75NTR
antibodies completely abolished estrogen's effects, caus-
ing IL-1β levels to be no different from those seen in the
control-pellet (OVX) replaced NMDA-lesioned group.
Note that anti-p75NTR treatment had no effect on the
control-replaced group.
Regulation of IL-1β mRNA and ICE activity
To determine the locus of hormone action on this
cytokine, IL-1β mRNA levels and the activity of the inter-
leukin-converting enzyme (ICE or Caspase-1) was meas-
ured. As shown in Figure 4A, RT-PCR analysis indicated
that the lesion substantially increased IL-1β mRNA (F1,12:
146.85; p < 0.05) at 24 h, however, estrogen pretreatment
did not affect mRNA expression (F1,12: 0.01, p > 0.05).
Furthermore, activity levels of caspase-1, which cleaves
the pro-peptide to mature IL-1β, were not regulated by
lesion or estrogen treatment (F5,30: 0.99; p > 0.05) at 24 h,
IL-1β regulation by lesion and estrogen treatmentFigure 3
IL-1β regulation by lesion and estrogen treatment: Olfactory bulb lesions significantly increased local IL-1β expression at 6 and 
24 hours post injury (6 hpi, 24 hpi). Estrogen treatment (OVX+E) attenuated IL-lβ at 6 hpi, and this effect was more pro-
nounced at 24 hpi. At 24 hpi, anti-p75NTR treatment abolished estrogen's effects on IL-1β. Anti-p75NTR had no effect on IL-
1β expression in control pellet-replaced (OVX) animals. Bars represent means ± SEM, n = 6 per group. Sham: Sham lesion, 
Lesion+Vehicle: NMDA injection with pre immune serum, Lesion+Anti p75: NMDA injections with anti p75NTR antibodies. 
*:p < 0.05.
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BMC Neuroscience 2005, 6:58 http://www.biomedcentral.com/1471-2202/6/58(Figure 4B), suggesting that this pathway is not initially
responsible for the increase in activated IL-1β.
pJNK expression
C-jun kinase activation was determined using antibodies
specific for the phosphorylated form of the protein
(pJNK) and normalized to total JNK protein (Figure 5).
Histogram shows the ratio of pJNK2/JNK at 6 and 24
hours post injury (hpi). JNK is one of the signaling mole-
cules activated by IL-1β when the latter is bound to its
receptor. As shown in Figure 5, pJNK2, but not pJNK1,
was increased by lesion at 6 h (F2,30: 19.22, p < 0.05) and
remained activated at 24 h (F2,30: 19.9, p < 0.05). pJNK1,
on the other hand, was constitutively active, which is typ-
ical for this isoform. JNK2 has a higher affinity for c-jun
[36], and activated JNK2 translocates to the nucleus, while
pJNK1 generally remains in the cytoplasmic compartment
[37]. Post hoc analysis indicated that estrogen treatment
JNK activity following olfactory bulb lesionsFigure 5
JNK activity following olfactory bulb lesions: JNK activation was measured by Western blot assay using phospho-specific (p) 
antibodies, and pJNK2 expression was normalized to total JNK2 protein. JNK1 was constitutively active in all cases. Virtually 
no pJNK2 was seen in the sham-injected controls in either control or estrogen-replaced animals. Bulb lesions significantly 
increased pJNK2 at 6 h after the lesion. At 24 h, pJNK2 levels were still elevated in the control-replaced (OVX) lesioned ani-
mals but significantly attenuated in the estrogen-treated (OVX+E) lesioned group. Anti-p75NTR reversed the effects of estro-
gen on pJNK2 activation at 24 h, although it had no effect on the control-pellet group. Two representative examples are shown 
from each treatment condition in the Western blot images. Histogram bars represent means+SEM for the entire group (n = 6). 
Sham: Sham lesion, Lesion+Vehicle: NMDA injection with pre immune serum, Lesion+Anti p75: NMDA injections with anti-
p75NTR antibodies. *:p < 0.05.
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BMC Neuroscience 2005, 6:58 http://www.biomedcentral.com/1471-2202/6/58(OVX+E) attenuated pJNK2 activation in lesioned ani-
mals at 24 h as compared to control replaced animals.
However, concurrent injection of NMDA+antip75NTR
abolished estrogen's effects on pJNK2 at 24 h, such that
the relative activation of this molecule was no different
from that of control-treated (OVX) animals.
Prostaglandin E2 (PGE2) levels
At 6 h after the lesion, PGE2 levels in the olfactory bulb
were no different from sham controls (F2,30: 0.21, p >
0.05; Figure 6), indicating that this marker occurs later in
the inflammatory cascade. At 24 hours post injury, there
was a 2-fold increase in PGE2 levels in lesioned animals
that were deprived of estrogen, while estrogen treatment
completely attenuated this increase in PGE2. Anti-p75NTR
antibodies completely eliminated estrogen's effects, caus-
ing PGE2 levels to rise similar to those seen in the control-
replaced (OVX) animals. Note that as with IL-1β, anti-
p75NTR treatment had no effect on PGE2 levels in the
control-replaced group.
MMP-9 activity
The 96 kD metalloproteinase MMP-9 is secreted by several
cell types and is activated by cytokines via the JNK/NFkB
PGE2 levels in the lesioned olfactory bulbFigur  6
PGE2 levels in the lesioned olfactory bulb: PGE2 expression was not altered by lesion or hormone treatment at 6 h post injury 
(6 hpi). However, at 24 hpi, PGE2 expression increased 2-fold in the control-pellet (OVX) replaced lesioned groups, while this 
increase was not seen in the estrogen-treated (OVX+E) lesioned animals. However, anti-p75NTR treatment completely abol-
ished estrogen's suppressive effects, making this group indistinguishable from the control pellet replaced, lesioned animals. Bars 
represent means ± SEM, n = 6 per group. Sham: Sham lesion, Lesion+Vehicle: NMDA injection with pre immune serum, 
Lesion+Anti p75: NMDA injections with anti-p75NTR antibodies. *:p < 0.05.
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BMC Neuroscience 2005, 6:58 http://www.biomedcentral.com/1471-2202/6/58pathways. To test whether the lesion influenced expres-
sion of MMP-9, both mRNA expression of this gene and
functional activation of its protein were analyzed by RT-
PCR (Figure 7A) and gelatin zymography (Figure 7B),
respectively. While MMP-9 mRNA expression was
increased in olfactory bulb lysates 24 h after the lesion
(F1,12: 200.32; p < 0.05; Figure 7A), estrogen treatment
resulted in a small but signifcant reduction of MMP-9
mRNA (F1,12: 12.4; p < 0.05, main effect of hormone).
Lesion-induced increases in MMP-9 mRNA were paral-
leled by increased MMP-9 activity at 24, but not 6 hours
post injury (data not shown), as assayed by gelatin
zymography. At 24 hpi, there was a significant increase in
MMP-9 gelatinolytic activity as a result of the lesion (F2,30:
MMP-9 regulationFigure 7
MMP-9 regulation: (A) MMP-9 mRNA was assayed by RT-PCR, and normalized to cyclophilin RNA. MMP-9 mRNA was signifi-
cantly increased by lesion, and estrogen teatment resulted in a small but signficant decrease in MMP-9 mRNA expression. (B) 
MMP-9 activity was measured by gelatin zymography at 6 and 24 h post injury, and representative examples from each group 
are shown here. The location of the lytic area corresponded to the expected size of MMP-9 (96 kD), indicated by the filled-
arrow head, as well as that of a positive control (conditoned media from endothelial cells). Line-arrow head indicates pre-
stained protein size marker (86 kD). Virtually no MMP-9 activity was apparent in the sham-injected animals. At 24 h after 
lesion, olfactory bulb lesions increased MMP-9 activity, although this was attenuated in the estrogen-treated (OVX+E), lesioned 
animals. Estrogen-treated lesioned animals that received anti-p75NTR, however, had MMP-9 activity that was similar to that of 
the control-pellet (OVX) replaced lesioned animals. Histogram represents means+SEM of the measured lytic area for MMP-9 
at the 24 h time point, n = 6 per group. Sham: Sham lesion, Lesion+Vehicle: NMDA injection with pre immune serum, 
Lesion+Anti p75: NMDA injections with anti p75NTR antibodies. *:p < 0.05.
Cyclophilin
A OVX-Sham OVX-Lesion Est-Sham Est Lesion
MMP-9
B
24 hpi
OVX ESTROGEN
M Ctrl SHAM LESION LESION SHAM LESION LESION
+ VEH + αP75 + VEH + αP75
0.00
0.25
0.50
0.75
1.00
1.25
24 hpi
M
M
P
-9
m
R
N
A
R
a
ti
o
o
f
o
p
ti
c
a
l
d
e
n
s
it
ie
s
OVX OVX Est Est
Sham Lesion Sham Lesion
*
*
M
M
P
-9
O
p
ti
c
a
l
d
e
n
s
it
y
0.0
0.5
1.0
1.5
2.0
24 hpi
Sh
am
Le
sio
n+
V
eh
Le
sio
n+
A
nt
i p
75
Sh
am
Le
sio
n+
V
eh
Le
sio
n+
A
nt
i p
75
* **
OVX OVX+EPage 7 of 18
(page number not for citation purposes)
BMC Neuroscience 2005, 6:58 http://www.biomedcentral.com/1471-2202/6/5810.12, p < 0.05), and estrogen treatment attenuated MMP-
9 activity in lesioned animals (F1,30: 21.15, p < 0.05). As
with other markers of inflammation measured here, post-
hoc analysis indicated that estrogen's effect on MMP-9
activity was reversed in estrogen-treated animals that
received anti-p75NTR treatment (F2,30: 3.84, p < 0.05; Fig-
ure 7B).
NGF expression
NGF expression in olfactory bulb lysates was measured by
an ELISA assay and normalized to total protein. NGF is
synthesized by a variety of cell types in the nervous and
immune system and one of its principal actions in the
brain is to promote growth and regeneration. As shown in
Figure 8, olfactory bulb lesions increased NGF levels when
measured at 24 h post lesion (F2,30: 24.154, p < 0.05) and
estrogen treatment also increased constitutive and
lesioned-induced expression of this growth factor (F2,30:
9.41, p < 0.05). However, anti-p75 antibodies did not
attenuate the lesion-induced increase in NGF expression
in either control or estrogen-treated animals, suggesting
that the anti-p75NTR specifically targets the inflammatory
cascade (IL-1β, PGE2, MMP-9) rather than repair
pathways.
NGF regulation by lesion and estrogen treatment:Figure 8
NGF regulation by lesion and estrogen treatment: Olfactory bulb lesions significantly increased NGF expression at 24 hours 
post injury (24 hpi). Estrogen treatment (OVX+E) increased basal and lesion-induced expression of NGF. However, anti-
p75NTR had no effect on NGF expression in control pellet-replaced (OVX) or estrogen-replaced (OVX+E) animals. Bars rep-
resent means ± SEM, n = 6 per group. Sham: Sham lesion, Lesion+Vehicle: NMDA injection with pre immune serum, 
Lesion+Anti p75: NMDA injections with anti p75NTR antibodies. *:p < 0.05.
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In previous studies, we have shown that the mechanical
and excitotoxic damage caused by an NMDA injection to
the olfactory bulb results in cell loss, astrocytosis and loss
of cholinergic function [4], as well as microglial activation
and a concomitant increase in the inflammatory cytokine
IL-1β [5]. The present studies confirm our earlier observa-
tions that the inflammatory response in the forebrain of
ovariectomized young adult rats is attenuated in animals
that were replaced with estrogen as compared to animals
that received a control (non-estrogen) pellet [5]. This
report also shows that estrogen treatment further stimu-
lates p75NTR expression, and that antibodies to p75NTR,
administered concurrently with the lesion, completely
abolish estrogen's anti-inflammatory effects. This study
supports the hypothesis that estrogen's anti-inflammatory
P75NTR regulation following olfactory bulb lesionsFigure 1
P75NTR regulation following olfactory bulb lesions: P75NTR expression was determined by Western blot assays (A) and 
receptor expression was quantified and normalized to a loading control (JNK) in the histogram (B). P75NTR was increased in 
lesioned animals, and estrogen treatment for 3 weeks prior to the lesion further enhanced the expression of this receptor. 
Two representative examples are shown of each treatment condition in the Western blots. Bars represent mean ± SEM, n = 6 
per group. (C) Specificity of p75NTR antibody: The antibody used in this Western assay recognizes a size appropriate band at 
75 kD, which is not seen when the membrane is probed in the absence of the primary antibody. Lane 1: PC12 cell lysate, Lanes 
2,3: olfactory bulb lysate. Key: OVX Sham: Ovariectomized female replaced with a control pellet, with sham injection, OVX 
lesion: ovariectomized female replaced with a control pellet, with NMDA injection, Est Sham: ovariectomized female replaced 
with an estrogen pellet, with sham injection, Est Lesion: ovariectomized female replaced with an estrogen pellet, with NMDA 
injection. *: p < 0.05.
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via the p75NTR. Since anti-p75NTR treatment had no
effect on control replaced lesioned animals, these data fur-
ther suggest that p75NTR expression in cells associated
with the microvessel wall, which estrogen stimulates in
lesioned animals only, may be a key cellular target of
estrogen's anti-inflammatory effects.
The inflammatory cascade contains several protein and
proteolipid mediators designed to contain the infectious
P75NTR expression in the lesioned olfactory bulbFigure 2
P75NTR expression in the lesioned olfactory bulb: Olfactory bulb sections from sham and NMDA lesioned animals that were 
either estrogen or control-pellet replaced were probed for p75NTR expression and counter-stained with a nuclear dye 
(DAPI). A low magnification photomontage of olfactory bulb illuminated for DAPI is shown in (a). P75NTR is normally 
expressed in the glomerular layer of the olfactory bulb (b), photographed from the region indicated by the solid line box in (a). 
P75NTR is poorly expressed in other regions of the olfactory bulb, an example of which is shown in (c), taken from the region 
indicated by the wire frame in (a). However, in a comparable region of the NMDA-lesioned animals, diffuse p75NTR staining is 
seen in cells and fibers at the injury site (d). In estrogen-treated, lesioned animals p75NTR immunoreactivity is seen in cells 
associated with the walls of microvessels (e; g), identified by their curved nuclei (f; h) surrounding a lumen. Arrows indicate the 
same cells photgraphed under fluorescein (p75NTR; e,g) or UV illumination (DAPI nuclear dye; f,h). A double-labeled cell pho-
tographed under both fluoresein and UV is shown in (i). P75NTR labeling was not seen in microvessel walls in lesioned animals 
that received a control pellet (j) or in sections from estrogen-replaced lesioned animals that were incubated without a primary 
antibody (immunohistochemical control, l). Corresponding nuclear dye images are in k and m. Magnification bar: b-d = 160 µm; 
e-m = 25 µm.
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IL-1β binds to its receptor and recruits the interleukin
receptor associated kinase (IRAK), and this complex sub-
sequently activates NFkB by association with TRAF-6, a
member of the TNF receptor associated factor family
[38,39]. Activation of signaling molecules, such as NFkB
and JNK, result in the coordinate transcriptional expres-
sion of several downstream inflammatory mediators such
as IL-6, IL-10, MMP-9 and cyclooxygenase-2 (COX-2), all
of which contain motifs for NFkB or AP-1 in their pro-
moter regions. The present study focused on a few key
mediators, representing the early and later points of the
inflammatory cascade. IL-1β, which is secreted by acti-
vated microglia/macrophages, is an early indicator of
inflammation, and is known to activate JNK [40]. Both
JNK and NFkB regulate MMP-9 [41] and COX-2 (the syn-
thesizing enzyme for PGE2) [42]. In the present study, the
lesion resulted in an early increase in IL-1β, JNK, and
MMP-9 and a delayed increase in PGE2. All these indica-
tors were attenuated in lesioned animals that received
Regulation of IL-1β mRNA and the interleukin-converting enzymeFig re 4
Regulation of IL-1β mRNA and the interleukin-converting enzyme: (A) mRNA from lesioned or sham injected animals, with 
estrogen or control pellets was reverse transcribed and amplified using primers specific for IL-1β and cyclophilin. PCR product 
was fractioned on an agarose gel and photographed under UV illumination. An image of these gels is shown here, with 4 repre-
sentative animals from each group. At 24 h post injury, NMDA lesions increased IL-1β mRNA, however, estrogen-treated 
(OVX+E) animals were no different from the control-pellet (OVX) treated animals. (B) Since the mature form of IL-1β is 
obtained through cleavage of IL-lβ precursor protein by caspase-1, activity for this enzyme was also assayed. Neither NMDA 
lesions nor estrogen treatment caused any significant changes in caspase-1 activity at 24 h post injury. Histogram bars repre-
sent means ± SEM for the entire group (n = 6). *:p < 0.05.
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p75NTR antibodies. These data strongly support the
hypothesis that p75NTR is an important mediator of
estrogen's anti-inflammatory effects. While the mecha-
nism of p75NTR anti-immune action is not yet known,
one possibility is that p75NTR may interfere with IL-1β
signaling pathways by competing for a limited pool of
IRAK. NGF/p75NTR complexes are also capable of recruit-
ing IRAK [32], and may therefore reduce the ability of
interleukin receptor ligand complexes to activate NFkB or
JNK, and consequently, hamper transcription of inflam-
mation-related genes.
Identified as the first neurotrophin receptor [43,44],
p75NTR has been implicated in both survival and apop-
totic pathways [45]. While p75NTR interacts with the
receptor tyrosine kinases, or trks, it has independent sign-
aling activities mediated through the ceramide and JNK
pathways as well [46]. P75NTR also has significant
homology with a family of cell death molecules, such as
TNFr and Fas (see [45,47] for reviews) and has been
shown to promote apoptotic cell death in PC12 cells [48],
retinal cells [49], oligodendrocytes [50], Schwann cells
[51] and otic vesicles [52]. P75NTR expression also
increases following injury, such as spinal cord injury
[27,53]. More recently, studies have implicated p75NTR
in the regulation of the inflammatory response, ranging
from suppression of MHC molecules to preventing the
transmigration of leukocytes. In hippocampal explant cul-
tures, endogenous neurotrophins produced by neurons
appear to control the antigen presenting ability of micro-
glia, and neurotrophins, via p75NTR, suppress MHC II
molecules [28]. P75NTR has also been localized to
peripheral monocytes, and NGF, via p75NTR, prevents
monocyte transmigration through the blood brain barrier
[29]. In p75 knock-out animals, the severity of
inflammation caused by a cranial nerve injury [54] or
experimental allergic encephalomyelitis [24] is signifi-
cantly greater as compared to wildtype controls. The
p75NTR null animals had increased staining of activated
microglia, and a massive recruitment of T-lymphocytes at
the lesion site, indicative of increased permeability of the
blood brain barrier [54]. The blood brain barrier serves to
exclude peripheral cells, specific proteins and molecules
from the brain, and p75NTR induction in endothelial
cells following experimental allergic encephalomyelitis
[24] suggests that this receptor may serve to maintain the
integrity of the blood brain barrier. The present study
indicates that estrogen exploits p75NTR-dependent anti-
inflammatory mechanisms, and that this action may also
occur at the blood brain barrier. In fact, estrogen itself is
known to reduce transport across the blood brain barrier
in injured [55,56] and non-injured animals [33] and
reduces monocyte migration into the brain following
ischemia [6].
Local levels of inflammatory cytokines such as IL-1β after
traumatic neural injury are derived from two sources: ini-
tially from the activation of local microglia and eventually
from the influx of circulating macrophages (and their
products) that enter the brain due to progressive changes
in the blood brain barrier. At 6 h after injury, estrogen
treatment has a very modest effect on the IL-1β levels, and
consequently, has little or no effect on JNK2 activation,
which is activated by IL-1β/IL receptor complexes. At 24 h,
however, estrogen markedly suppresses IL-1β levels and
this is reflected in a pronounced decrease in JNK activa-
tion at this time point. This biphasic effect of estrogen on
IL-1β suggests that estrogen may exert its effects not by act-
ing on local microglia, but by reducing the pool of acti-
vated immune cells that are recruited to a central lesion
site from circulatory sources, either by maintaining the
integrity of the blood brain barrier, or by direct action on
monocytes/macrophages. Our recent studies show that
both possibilities are likely. For example, estrogen treat-
ment suppresses cytokine production in circulating
immune cells, but not microglia, when challenged ex vivo
with LPS [57]. Furthermore, estrogen treatment also
reduces permeability of the blood brain barrier as meas-
ured by extravasation of Evan's blue dye [33]. This latter
hypothesis is also supported by the fact that estrogen fails
to suppress IL-1β mRNA or the activity of caspase-1,
which cleaves precursor IL-1β to its mature active form, at
24 hours post injury. This suggests that estrogen may not
directly alter the availability of a local pool of IL-1β by
canonical pathways but acts to gate the entry of cytokines
from circulating immune cells or those produced by
microvessel-associated cells.
Vascular permeability and leukocyte invasion can be
increased by matrix remodelling resulting from the
actions of the MMP family [58,59]. MMP-9 increases fol-
lowing experimentally induced stroke, and the availability
of this proteinase directly contributes to the size of the inf-
arct [60]. Several factors may control MMP-9 regulation
and one report indicates that NGF associates with
p75NTR to downregulate MMP-9 activity [61]. Estrogen
also has been shown to reduce MMP-9 mRNA [6,62]
which likely contributes to its neuroprotective actions. In
the present study, estrogen-induced decreases in MMP-9
were reversed by anti-p75NTR. Although this study does
not address the source of MMP-9 or its substrate, it may be
the case that estrogen-induced reductions in MMP-9 pro-
vide the means for maintaining the integrity of the blood
brain barrier in these animals.
The observation that estrogen treatment exacerbates
p75NTR expression in lesioned animals is surprising in
view of the many studies where estrogen has been shown
to decrease p75NTR mRNA [63-65] and protein [66,67]
expression. However, these studies were performed inPage 12 of 18
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therefore be representative of neuronal p75NTR, as has
been shown in basal forebrain neurons [65]. This was also
the case in a more recent study where estrogen suppressed
p75NTR expression in hippocampal neurons following
ischemic injury in male gerbils [68]. Moreover, the same
study also reported that p75 expression in the hippocam-
pus was first seen 48 h after injury. The present study, on
the other hand, describes a very early event in the injury
process. Furthermore, the only region where p75NTR
expression was regulated differentially was in the microv-
asculature of estrogen-treated, lesioned animals. This spe-
cificity may explain why anti-p75NTR treatment
abolished estrogen's effects on the inflammatory cascade
but had no discernable effects on the placebo-replaced
animals. We hypothesize that the early increase in micro-
vascular p75NTR may play a significantly different role in
inflammation as compared to the later expression of neu-
ronal p75NTR.
The present study shows that estrogen replacement to ova-
riectomized young females suppresses the inflammatory
response following neural injury; however, hormonal
regulation of the inflammatory response is not always
benign. While estrogen reduces experimentally induced
inflammation in the anterior chamber of the eye [69],
lungs [70] and the tibiotarsal joint in adjuvant-induced
arthritis [71,72], this hormone promotes inflammation in
the prostate [73,74], and stimulates edema [75], vascular
permeability and influx of macrophages in the uterus [76-
79]. Even in models of neurogenic inflammation, such as
the present study, estrogen treatment is not uniformly
neuroprotective. For example, a similar 3 wk regimen of
estrogen to reproductive senescent females does not atten-
uate the production of IL-1β, and actually exacerbates it
[5]. Furthermore, in these senescent animals, estrogen
fails to enhance p75NTR expression following a lesion
(data not shown). While the reasons for estrogen's dispa-
rate actions on different tissues is not clear, the present
study suggests that p75NTR may be one of the switches
that predict whether estrogen will exert neuroprotective or
neurotoxic effects. An important direction for this work
would be to test this hypothesis in the p75 knock-out
model or, preferably, a conditional p75NTR knock-out
animal, which eliminates the compensatory changes that
might occur as a result of developmental loss of p75.
Methods
Animals
Sprague Dawley females (~250 g, 4 months) were pur-
chased from Harlan Laboratories (IN) and maintained in
an AALAC-approved facility on a 12-h light: 12-h dark
cycle with lights on at 06:00 h, with food and water avail-
able ad libitum. All procedures were in accordance with
NIH and institutional guidelines governing animal
welfare. Several sets of animals were prepared, each with
internal controls. For convenience a chart is provided
below. For the p75 expression studies (Westerns blot anal-
ysis and immunohistochemistry), we used tissue from
four sets of animals that had been prepared for a previous
study, and related data from these animals is published in
[5]. Briefly, young adult animals were ovariectomized and
replaced with either control or estrogen pellets and 3
weeks later were assigned to either sham lesion or NMDA
lesion groups. Twenty four hours later, animals were sac-
rificed and the olfactory bulbs were dissected and later
harvested for proteins. A second set was prepared as above
for histological analysis, where animals were perfused fol-
lowing anesthetic overdose and the brains recovered for
histological processing (described later).
For p75NTR antibody studies, two sets of animals were
prepared: placebo or estrogen-replaced animals were
assigned to one of three groups: sham lesion,
NMDA+vehicle control (preimmune rabbit serum) or
NMDA+anti-p75NTR antibodies (made in rabbit). One
set of animals was sacrificed at 6 h after the lesion, and the
second set at 24 h after the lesion. In all sets, each
treatment group consisted of 5-6 animals per group (See
Table 1). Specific surgical procedures are detailed below.
Table 1
Summary P75NTR Western P75NTR Immuno RNA analysis Antip75 Expt 6 h Antip75 Expt 24 h
Sham 
Lesion
NMDA Sham 
Lesion
NMDA Sham 
Lesion
NMDA Sham 
Lesion
NMDA+ 
Veh*
NMDA+Anti 
p75NTR
Sham 
Lesion
NMDA+ 
Veh*
NMDA+Anti 
p75NTR
Control 
Pellet
6 6 5 6 6 6 6 6 6 6 6 6
Estrogen-
Pellet
6 6 6 6 6 6 6 6 6 6 6 6
Analysis Western blots Immuno 
histochemistry
RT-PCR analysis of 
IL-1β, MMP-9
IL-1β, pJNK, PGE2, MMP-9, IL-1β, pJNK, PGE2, MMP-9 caspase-3, 
caspase-1
* = Pre immune serumPage 13 of 18
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the most effective concentration of anti-p75NTR antibod-
ies (n = 12) and (b) to ensure that there were no differ-
ences between animals injected with NMDA and
NMDA+preimmune serum (the vehicle for the anti-
p75NTR antibody) (n = 6).
Surgical techniques
Ovariectomies: As previously described [4,66,80,81], ani-
mals were anesthetized with ketamine (87 mg/kg)/xyla-
zine (13 mg/kg) and bilateral ovariectomies were
performed using a dorsal midline incision inferior to the
palpated rib cage and kidneys. Ovaries and surrounding
tissue were removed and 60-day time-release 17β estra-
diol pellets (1.0 mg) or control pellets (Innovative
Research, FL) were inserted subcutaneously (s.c.) prior to
closing the incision. These pellets have been used exten-
sively in our work and have resulted in physiological lev-
els of plasma estradiol for periods of 3 to 6 weeks [4,5,66].
Stereotaxic surgeries
After 3 weeks of estrogen or control treatment, all animals
were anesthetized with ketamine (87 mg/kg)/xylazine (13
mg/kg) and placed in a rodent stereotaxic apparatus. Skin
and cranial fascia were resected and the skull exposed.
Two small craniotomies were made in all rats assigned to
lesion groups, to expose the olfactory bulbs at the follow-
ing coordinates: 7.6 mm anterior to bregma and 1.0 mm
lateral to the sagittal suture. The tip of a Hamilton syringe
needle was briefly lowered to a depth of 3.4 mm, and
immediately raised by 0.2 mm to create a trough. A total
of 2 µl (1 µl per side) of 50 nM NMDA was injected at a
rate of 0.2 µl/30 s. For anti-p75NTR experiments, 1 µL of
50 nM NMDA + 2 µL preimmune rabbit serum (L groups)
or 1 µL 50 nM NMDA + 1.5 µL preimmune rabbit serum
+ 0.5 µL ap75NTR (P groups) was injected in each bulb at
a rate of 0.5 µL/30 s. After injections, the needle was raised
slowly, craniotomies filled with gel-foam, and scalp
sutured with wound clips. Surgical controls were anesthe-
tized, restrained in the stereotaxic apparatus and their
scalp and cranial fascia resected and reclipped. Other
reports [82] and our previous studies [5] indicate that at
24 h post injury a saline injection is not an appropriate
control since the injection itself results in injury.
The anti-p75NTR antibody used here (Chemicon, CA,
AB1554) recognizes the extracellular domain of the
p75NTR and has been shown to block NGF/p75NTR
interactions [83-85]. This antibody is not recommended
for Western blots (hence a different antibody was used for
the Western blot assays), but can be used for immunohis-
tochemistry. Both the neutralizing antibody used here
and the antibody used for Westerns revealed similar stain-
ing patterns in the olfactory bulb when used for
immunohistochemistry.
Animals were sacrificed at 6 h and 24 h after stereotaxic
surgery by rapid decapitation and trunk blood was
collected for estimation of estradiol content by radioim-
munoassay (Diagnostic Systems Laboratories, TX). Olfac-
tory bulbs were rapidly removed and stored at -80°C.
Proteins were isolated from the entire olfactory bulb using
previously established procedures [4,80,81] and total pro-
tein concentrations were determined using the BCA pro-
tein assay kit (Pierce, IL). In some cases, bulbs were
processed for RNA extraction described below.
Western blot analysis
Equal amounts of total protein from tissue lysates were
size-fractionated on a polyacrylamide gel, transferred to a
nylon membrane (Hybond C-Super, Amersham, NJ) and
analyzed for p75NTR and pJNK. Blots were also probed
for total JNK expression as a loading control, since this
protein did not vary with lesion or estrogen treatment
[81]. Membranes were blocked with 5% milk in 1 × Tris
Buffered Saline + 0.05% Tween (TTBS) solution for 1 h,
followed by incubation with the primary antibody in
milk-TTBS (1/ 1500 Ms × NGF Receptor (p75NTR;
MAB365), Chemicon, CA; 1/2500 anti-active JNK,
Promega, WI; 1/2000 JNK, Santa Cruz, CA) for 1 h at
room temperature (p75NTR) or overnight at 4°C (pJNK,
JNK). Blots were washed with TTBS (3 × 10 min) and pri-
mary antibody was detected using an HRP-conjugated sec-
ondary antibody in milk-TTBS (anti-mouse IgG 1/3000
for p75NTR, Transduction Laboratories, KY; 1/6000 anti-
rabbit IgG for pJNK, Promega, WI; 1/2000 anti-rabbit IgG
for JNK, Santa Cruz, CA). All incubations were performed
at room temperature with gentle shaking. After the last
wash step, an enzyme-catalyzed chemiluminescent rea-
gent (Renaissance NEN, MA) was used for immunodetec-
tion. Signals were detected using X-ray film and bands
quantified by densitometric analysis (Molecular Analyst,
Bio-Rad, CA) and normalized to JNK expression.
Immunohistochemistry for p75NTR
Immunohistochemistry was performed on olfactory bulb
sections of placebo- or estrogenreplaced ovariectomized
young-adult animals that were subject to olfactory bulb
lesions as outlined above and sacrificed 24 h later.
Sections were prepared using the NeuroScience Associates
Multibrain technology and some sections from this set
were used in previous assays to detect activated microglia
[5]. Briefly, animals were anesthetized with 0.6 mL pento-
barbital solution (50 µg/mL pentobarbital, 10% ethanol,
40% propylene glycol) and perfused transcardially with
PBS followed by 4% paraformaldehyde. Brains were
removed from the skull and post-fixed in 4% paraformal-
dehyde (2 h). Brains were then shipped to NeuroScience
Associates (Knoxville, TN), where they were treated with
20% glycerol and 2% dimethylsulfoxide to prevent freeze
artifacts, and then embedded coronally in groups of 14-16Page 14 of 18
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through the entire olfactory bulbs were obtained with an
AO 860 sliding microtome and collected in 4 × 6 array of
containers filled with 10% phosphate-buffered formalde-
hyde. After 24 h, sections were rinsed and transferred into
Antigen Preserve solution (50% PBS pH 7.0, 50% Ethyl-
ene glycol, 1% PVP) for storage and shipping. Prior to use
in immunohistochemistry, sections were rinsed in PBS
and mounted on gelatin coated glass slides. P75NTR was
detected by fluorescence-labeled secondary. Sections were
incubated with block solution and followed by overnight
incubation with the primary antibody (1/200; mouse
anti-NGFR; Chemicon, CA) diluted in PBS with 3% goat
serum and 0.4% Triton. Controls were incubated with
diluent only. Following washes, sections were incubated
with a rat-adsorbed FITC-conjugated Fab specific second-
ary antibody (1/160 goat anti-mouse, Vector Labs, CA)or
AlexaFluor 488 (1:2000 for goat anti-mouse, Invitrogen,
CA) for 45 min at room temperature. Sections were then
washed and coverslipped using a fluorescence-compatible
mounting media which contained DAPI, a nuclear dye.
The presence of glomerular staining in the bulb was also
used as a positive control. Sections from the midpoint of
the bulb (around the injection site) were examined under
fluorescence illumination for FITC for the presence of
p75NTR immunostaining. Five sections were examined
from each animal and 5-6 animals were examined per
treatment group.
Caspase-1 and Caspase-3 assays
A commercial kit was used to determine Caspase-1 (inter-
leukin-1 converting enzyme) and Caspase-3 activity
(Promega, WI) as before [81], using manufacturer's rec-
ommended procedures. Briefly, blanks, samples and
negative controls were pipetted into a flat-bottom, black
96-well plate and incubated at 30°C for 30 minutes.
Plates were then incubated with Caspase-1 (ICE) or
CCP32 substrate (Ac-YVAD-AMC and Ac-DEVD-AMC,
respectively) at 30°C for 60 minutes. A standard curve was
prepared just prior to reading at 360 nm (excitation) and
460 nm (emission) in a fluorescence microplate reader
(BioTek, VT). Measurement of liberated AMC, interpo-
lated from standard curves, was normalized to protein per
unit time (min).
Enzyme-linked immunosorbent assay (ELISA)
Commercial kits for IL-1β (R&D Systems, MN) and PGE2
(Cayman Chemical, MI) were used to determine cytokine
and prostaglandin levels in tissue lysates, using proce-
dures recommended by the manufacturers [5]. Briefly,
standards, controls, samples and a biotinylated (IL-1β) or
acetylcholinesterase-linked (PGE2) secondary antibody
were pipetted into 96-well plates pre-coated with antibod-
ies specific for rat IL-1β and PGE2, and incubated at RT for
2 h (IL-1β) or 4°C overnight (PGE2). Following washes,
plates were sequentially incubated with streptavidin per-
oxidase (IL-1β: 2 h) or Ellman's reagent (PGE2: 60-90
min) and substrate solution for 30 min (IL-1β). Plates
were read at 450 nm (IL-1β) or 405 nm (PGE2) in a micro-
plate reader (Bio-Tek, VT). Standard curves were estab-
lished from optical densities of wells containing known
dilutions of standard, using KC3 software (Bio-Tek, VT)
and sample measurements were interpolated from stand-
ard curves.
Reverse transcription-polymerase chain reaction
IL-1β and MMP-9 gene expression was determined by
semi-quantitative reverse transcription-polymerase chain
reaction (RT-PCR). RNA was extracted using the TRIZOL®
Reagent RNA extraction method [86], followed by further
purification with the Qiagen RNeasy Kit (Qiagen, CA).
The RNA concentration was determined using the
RiboGreen® RNA Quantification Kit (Molecular Probes,
OR). Reverse transcription of total RNA (2 µg) was per-
formed with the Gibco Superscript™ First Strand Synthesis
System. PCR of the newly synthesized cDNA (8 ng) was
performed using PCR Supermix (Invitrogen, CA; primer
conc. 0.25 µM; 200 µM dNTP; 1× PCR Buffer, 1.5 mM
MgC12, 20 U recombinant Taq DNA polymerase). IL-1β
(5'-3': IL-1β-For TTG AAT CTA TAC CTG TCC TGT GTG;
IL-1β Rev TGA CTT GGC AGA GGA CAA AGG) PCR cycles
were as follows: 95°C 2 min; 30 cycles of 95°C 30 sec,
60°C 1 min, 72°C 2 min. PCR reactions for MMP-9 were
performed using previously published primers [11]. PCR
conditions were as follows: 95°C for 5 min followed by
40 cycles at 92°C for 1 min, 56°C for MMP-9 for 1 min,
and 72°C for 1 min. Cyclophilin (5'-3': CPI-1, TGG TCA
ACC CCA CCG TGT TCT TCG; CP1-2 TGC CAT CCA GCC
ACT CAG TCT TGG) was used to normalize IL-1β and
MMP-9 expression. The PCR cycles for cyclophilin are as
follows: 95°C 2 min, 20 cycles of 95°C 30 sec, 62°C 1
min, 72°C 2 min. PCR reactions were performed on a Per-
kin-Elmer Thermal Cycler 480. Initial analyses were per-
formed to ensure that IL-1β and cyclophilin were
amplifying in the linear range. The PCR reaction was sep-
arated on a 1.5% agarose gel and quantified using Molec-
ular Analyst™ (BioRad, CA). To avoid quantitation
artifacts, only samples loaded on the same gel were ana-
lyzed. Hence, for each treatment group, 4 independent
samples were analyzed. In every case, only a single band
of the expected size was detected and bands amplified by
each primer set was sequenced (Gene Technologies Labo-
ratory, TAMU) and determined to be homologous to rat
IL-1β and MMP-9 gene sequences.
Gelatin zymography
Procedures used here are a modification of our previous
protocol using culture media [57]. Equal amounts of total
protein were size fractionated on a 10% polyacrylamide
gel containing 0.01% gelatin, along with prestainedPage 15 of 18
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included (conditioned media from human umbilical vein
endothelial cells; kind gift of G.E. Davis, TAMUS HSC).
After electrophoresis, the gels were rinsed with MQ water
and then incubated with renaturing buffer (2% Triton X-
100 in MQ) at room temperature for 1 h with 3 buffer
changes. Gels were then rinsed 3× with MQ water and
incubated with developing buffer (50 mM Tris, 0.2 M
NaCl, 5 mM CaCl2 0.02% Brij 35) overnight at 25°C with
gentle shaking. After a brief rinse with MQ water, gels were
stained with a 0.25% coomassie blue solution (50%
methanol, 20% acetic acid) for 1 h and destained in 20%
methanol: 10% acetic acid. Gels were dried at 50°C for 1
h, and later digitized. A standard densitometric program
(Quantity One, BioRad, CA) was used to calculate the
intensity of the lytic area.
Statistical analysis
Statistical analysis was performed using a statistical soft-
ware package (SPSS Inc, IL), and group differences were
considered significantly different at p < 0.05. Data was
subject to a two-way analysis of variance (ANOVA) with
hormone and lesion as independent variables. Planned
post-hoc comparisons were performed for the lesion vari-
able in those studies where there were three groups
(sham, lesion+vehicle (preimmune serum) and
lesion+anti-p75NTR).
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